The mission of ASC is to take our licensed patented line of MASCs through FDA pre-clinical and clinical trials establishing medical devices, pharmaceuticals, and medical treatments approved for marketing. ASC plans to actively pursue commercialization of its tissue regeneration technologies which replace the need of donor cells. The MASCs will essentially become known as “cells in a bottle” providing a specified dose of adult stem cells for specific therapies, which is an enormous advantage over harvesting cells from a patient’s body. Our MASCs have the potential to produce a minimum of over two hundred therapeutic treatments.
ASC’s scientific founder Dr. Paul Lucas discovered and developed the company’s MASCsTM platform. The journey to form ASC began 30 years ago. In 1986 Dr. Lucas became interested in the identity of the cells that responded to bone morphogenetic protein (BMP, a protein that causes bone to form in muscle or under the skin). He continued that interest over the next 30 years. The initial discovery was a population of stem cells in embryonic chick muscle. Not only did these cells respond to BMP to form bone cells but they also responded to a non-specific agent, dexamethasone, to differentiate not only into osteoblasts, but skeletal muscle cells, fat cell, and cartilage cells. Dr. Lucas became an Associate Professor in the Department of Orthopedic Surgery at New York Medical College in 1996. He began research into the possibility that mammals (first rats and then humans) had the same type of stem cells seen in embryonic chick muscle. Not only do adult rats and humans have the same stem cell, but the stem cell was capable of differentiating into many more cell types than first realized.
Dr. Lucas’ research has focused on the isolation, characterization, and use in regeneration of these stem cells ever since. The stem cells (multipotent adult stem cells or MASCs) have been found in adult rats, mice, rabbits, dogs, goats, and humans. MASCs have been isolated from several tissues other than skeletal muscle, including skin. MASCs can differentiate into cells of all 3 dermal lineages (ectoderm, mesoderm, endoderm) which, together, make up the entire body. Papers describing the regeneration of peritoneum, articular cartilage, bone, and meniscus have been published. One for Chondrofelt which should be issued within the year, another for the manufacture of blood cells from MASCs, and the last for a Serum Free Media for the Growth and Mainte-nance of the MASCs.
In order to accomplish its goals of bringing its family of MASC products to fruition while remaining viable and profitable in this highly competitive field ASC Biosciences has acquired exclusive patent rights for the use of a biodegradable matrix to use alone or in conjunction with autologous adult stem cells for the repair of cartilage defects (i.e. osteoarthritis). ASC Biosciences also holds exclusive patent rights to a proprietary adult stem cell platform which is capable of forming nearly every tissue in the human body.
With its focus on MASCs, ASC Biosciences is taking stem cell technology in an entirely new and different direction. Currently, of the dozens of stem cell companies and biotech companies working on stem cell research, all use one or more of the following stem cell types – and ASC Biosciences uses none:
Currently, the only other company that is using adult stem cells for the purpose of regenerating tissue is a company using neural stem cells, which can only differentiate to nervous system cells. This makes ASC Biosciences the only stem cell company with the capability of manufacturing allogenic adult stem cells with the potential of unlimited differentiation and proliferation ability.
Are you as excited as we are about what the future holds for stem cell therapy?
We invite you to keep up with our progress by subscribing to our newsletter.